Hanmi Pharmaceutical: This Korean Pharma Giant's Stock Could Rebound More than 50%.
Hanmi Pharm Co Ltd (128940 KS)Â stock has fallen from recent highs after Boehringer pulled out of an oncology deal and short-sellers piled on the...
806 Views
The Chickens Are Ready to Roost
Several recent developments confirm our thesis that Inflectra's US sales in 2017 will fall far short of management's 2017 forecast. First, Pfizer's...
337 Views
More Harsh Reality from Teva
U.S. healthcare industry leaders from across the spectrum of industry segments continue to downplay the near-term adoption of biosimilars in the...
335 Views
Study Highlights Hurdles to U.S. Uptake of Inflectra
A new study (abstract attached) presented at the European Union League Against Rheumatism (EULAR) Conference highlights one of the main hurdles to...
286 Views
U.S. Remsima Expectations Too Optimistic
USFDA approved Celltrion’s Remsima, a biosimilar for JNJ’s Remicade, for use in treating rheumatoid arthritis, ulcerative colitis, Crohn’s, and...
335 Views